| | Advanced Search

 

Clark University Receives $1.45 Million from the John Templeton Foundation—Clark University was awarded a $1.45 million grant…

Pats’ Camp: Underway with high expectations—Gronk cleared, training camp kicks off Thursday in…

Giorgio: We Got Ours; Don’t Try to Get Yours—Giorgio: We Got Ours; Don’t Try to Get…

Horowitz: News Literacy: An Essential Skill in the Age of the Internet—Horowitz: News Literacy: An Essential Skill in the…

Dear John: Just A Few More Small Changes And She’ll Be Perfect!—Dear John, I’ve been seeing a guy for…

Massachusetts Gas Prices Down Five Cents—Massachusetts gasoline prices have dropped five cents from…

Angiulo: Non-Violent Drug Offenders May See Federal Prison Stays Shortened—Angiulo: Non-Violent Drug Offenders May See Federal Prison…

Smart Benefits: Patient-Centered Outcomes Research Institute Fee Due July 31—The Affordable Care Act created the Patient-Centered Outcomes…

Harvard Baseball’s Martin Dominates All-Star Skills Competition—Harvard Baseball's Martin Dominates All-Star Skills Competition

College Admissions: 6 Ways To Ace The College Interview—It can really make a difference...

 
 

New Breakthrough Links Diabetes + Alzheimer’s

Monday, July 02, 2012

 

New research reveals a link between brain insulin resistance (diabetes) and Alzheimer's disease

New research from Rhode Island Hospital has revealed a link between brain insulin resistance (diabetes) and two other key mediators of neuronal injury that help Alzheimer’s disease (AD) to propagate. The research found that once AD is established, therapeutic efforts must also work to reduce toxin production in the brain. The study, led by RI Hospital researcher Suzanne de la Monte, M.D., is published in the June 22, 2012, supplement of the Journal of Alzheimer’s Disease

“Brain insulin resistance (diabetes) is very much like regular diabetes,” de la Monte said. “Since the underlying problems continue to be just about the same, we believe that the development of new therapies would be applicable for all types of diabetes, including Alzheimer’s disease, which we refer to as Type III diabetes.”

De la Monte said that the study points out that once AD is established, therapeutic efforts should target several different pathways — not just one. "The reason is that a positive feedback loop gets going, making AD progress," she said. "We have to break the vicious cycle. Restoring insulin responsiveness and insulin depletion will help, but we need to reduce brain stress and repair the metabolic problems that cause the brain to produce toxins.”

Alzheimer's disease

Alzheimer’s disease is one of the most common degenerative dementias, and more than 115 million new cases are projected worldwide in the next 40 years. There is clinical and experimental evidence that treatment with insulin or insulin sensitizer agents can enhance cognitive function and in some circumstances help slow the rate of cognitive decline in AD. Alzheimer’s and other neurodegenerative diseases destroy the brain until the patients finally succumb. In order to effectively halt the process of neurodegeneration, the forces that advance and perpetuate the disease, particularly with regard to the progressive worsening of brain insulin/IGF resistance, must be understood.

A metabolic syndrome?

Growing evidence supports the concept that AD is fundamentally a metabolic syndrome that leads to abnormalities linked to brain insulin and insulin-like growth factor (IGF) resistance. In AD, brain insulin and IGF resistance and deficiencies begin early and worsen with severity of the disease. The rationale behind the progression of the disease is that insulin-resistance dysregulates lipid metabolism and promotes ceramide accumulation, thereby increasing inflammation and lipid metabolism, causing toxic ceramides to accumulate in the brain. The end result is increased stress that threatens the survival and function of neurons in the brain.

The present study was designed to gain a better understanding of how brain insulin resistance becomes progressive and contributes to the neurodegeneration in AD, focusing on the roles of ceramides and stress. The researchers studied the same brain samples used previously to demonstrate progressive impairments in brain insulin/IGF signaling with increasing severity of AD.

(The National Institutes of Health funded the study (grant #R01 AA11431, AA12908, AA16126). De la Monte’s principal affiliation is Rhode Island Hospital, a member hospital of the Lifespan health system in Rhode Island.  She also has an academic appointment at The Warren Alpert Medical School of Brown University. Their research is fully supported by Rhode Island Hospital and the Lifespan health system.)

 

Related Articles

 

Enjoy this post? Share it with others.

You Must be Logged In to Comment

Tracker Pixel for Entry